Displaying drugs 10326 - 10350 of 12422 in total
Lucanthone
One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46). It is currently being tested as a radiation sensitizer.
Investigational
Matched Description: … One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel …
Cyamemazine
Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).
Experimental
Matched Description: … class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. ... Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine ... actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of …
Amolimogene
Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV). Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia.
Investigational
Matched Description: … Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia …
N4-Hydroxycytidine
N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.[A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage. It has shown antiviral activity against Venezuelan equine encephalitis virus, and the human coronavirus HCoV-NL63 in vitro. N4-hydroxycytodine has been...
Experimental
Matched Description: … activity against the coronavirus family of viruses. ... new virions, resulting in the accumulation of inactivating mutations. ... A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of …
L-erythro-7,8-dihydrobiopterin
7,8-Dihydrobiopterin is an inhibitor of the enzyme dihydroneopterin aldolase (DHNA), which catalyzes the conversion of 7,8-Dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde.
Experimental
Matched Description: … 7,8-Dihydrobiopterin is an inhibitor of the enzyme dihydroneopterin aldolase (DHNA), which catalyzes ... the conversion of 7,8-Dihydrobiopterin to 6-hydroxymethyl-7,8-dihydropterin and glycolaldehyde. …
Camrelizumab
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
Investigational
Matched Description: … ED-SCLC After Failure of First Line Standard Therapy). ... is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of …
RSV-604
RSV-604 is under investigation in clinical trial NCT00416442 (Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.).
Investigational
Matched Description: … Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.). ... is under investigation in clinical trial NCT00416442 (Safety, Tolerability and Pharmacokinetic Study of …
Foralumab
Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
Investigational
Matched Description: … Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab …
Tilsotolimod
Tilsotolimod is under investigation in clinical trial NCT03865082 (Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)).
Investigational
Matched Description: … With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)). ... Tilsotolimod is under investigation in clinical trial NCT03865082 (Study of Tilsotolimod in Combination …
CRx-139
CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. The synergistic combination containing low doses of the...
Investigational
Matched Description: … CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting ... This novel synergistic combination is developed for the treatment of immuno-inflammatory diseases. ... It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid …
2-Hydroxyestradiol
2-Hydroxyestradiol is classified as an endogenous steroid, catechol estrogen, and metabolite of estradiol. It is also a positional isomer of estriol.
Experimental
Matched Description: … It is also a positional isomer of estriol. [A31630] ... 2-Hydroxyestradiol is classified as an endogenous steroid, catechol estrogen, and metabolite of estradiol …
Modithromycin
Modithromycin is under investigation in clinical trial NCT00270517 (Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia).
Investigational
Matched Description: … Another Antibiotic in the Treatment of Community Acquired Pneumonia). ... Modithromycin is under investigation in clinical trial NCT00270517 (Comparative Study of EDP-420 Versus …
BNT111
BNT111 is an investigational cancer immunotherapy under development for advanced melanoma. It consists of a fixed combination of mRNA-encoded, tumor-associated antigens.
Investigational
Matched Description: … It consists of a fixed combination of mRNA-encoded, tumor-associated antigens. …
TZP-102
TZP-102 is under investigation in clinical trial NCT01452815 (Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis).
Investigational
Matched Description: … of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis). ... TZP-102 is under investigation in clinical trial NCT01452815 (Affects of Once-daily Oral Administration …
Cediranib
The novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
Investigational
Matched Description: … It is being developed clinically as a once-daily oral therapy for the treatment of cancer. ... quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of …
Mitoquinone
Mitoquinone is based on a novel technology, targeted lipophilic cations, that transport and concentrate antioxidants into the mitochondria -- organelles inside cells that provide energy for life processes -- where they accumulate up to a thousand fold. In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct...
Investigational
Matched Description: … the sporadic form of Parkinson's disease. ... link between mitochondrial dysfunction and the pathogenesis of Parkinson's disease. ... In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct molecular …
Leptin
Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. These people are said to be resistant to the effects of leptin, in much the same way that people with type 2 diabetes are resistant to the effects of...
Investigational
Matched Description: … type 2 diabetes are resistant to the effects of insulin. ... These people are said to be resistant to the effects of leptin, in much the same way that people with ... signal that reduces appetite, in general, obese people have an unusually high circulating concentration of …
Shark liver oil
Shark oil is extracted from the livers of sharks, which can account for up to 25% of their total body weight. The 3 main targeted species are the deep sea shark (Centrophorus squamosus), the dogfish (Sqaulus acanthias), and the basking shark (Cetorhinus maximus). Shark oil is a rich source of...
Experimental
Matched Description: … Shark oil is extracted from the livers of sharks, which can account for up to 25% of their total body ... Shark oil is a rich source of alkylglycerols and squalene, with relatively low amounts of n-3 polyunsaturated ... However the major component is considered to be squalene, which may range up to 90% of the shark oil, …
CRx-401
CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain. It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent. In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been...
Investigational
Matched Description: … It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic ... dose of bezafibrate, an anti-cholesterol agent. ... In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been observed to have …
Amcipatricin
Amcipatricin has been used in trials studying the treatment of Cryptococcosis or Aspergillosis Infections. Amcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of systemic fungal infections. In preclinical models, SPK-843 shows...
Investigational
Matched Description: … SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward ... Amcipatricin has been used in trials studying the treatment of Cryptococcosis or Aspergillosis Infections ... SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of …
rhMBL
rhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL). Over 10 percent of the general population is estimated to be MBL-deficient. Natural MBL is a 400-700kDa oligomer made of 3 identical 32kDa peptide...
Investigational
Matched Description: … in individuals with low levels of Mannose-Binding Lectin (MBL). ... Over 10 percent of the general population is estimated to be MBL-deficient. ... Natural MBL is a 400-700kDa oligomer made of 3 identical 32kDa peptide chains. …
Gold
A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
Experimental
Matched Description: … Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts. ... It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. …
Froniglutide
Glymera is under investigation in clinical trial NCT01658501 (Phase 2b Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM).
Investigational
Matched Description: … Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM). ... Double-blind, Placebo- and Active-controlled, Parallel-group Study to Assess the PD Response and Safety of …
AI-850
AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.
Investigational
Matched Description: … used to treat a variety of solid tumors. ... AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product …
Sisunatovir
Sisunatovir is under investigation in clinical trial NCT04267822 (Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV).
Investigational
Matched Description: … Sisunatovir is under investigation in clinical trial NCT04267822 (Study of RV521 in the Treatment of …
Displaying drugs 10326 - 10350 of 12422 in total